DarioHealth Business Summary

DarioHealth Corp. (DRIO) is a digital therapeutics leader generating revenue through a high-margin B2B2C Software-as-a-Service (SaaS) model, supplemented by strategic pharmaceutical partnerships and direct-to-consumer device sales. Its integrated "whole-person" platform leverages AI-driven behavioral data and connected hardware to manage chronic conditions across five segments: diabetes, hypertension, weight management, musculoskeletal (MSK) health, and behavioral health. As of February 2026, the company is executing a transition to a recurring revenue model with a commercial pipeline valued at $69 million, aiming for cash flow breakeven by late 2026. Dario competes primarily with Teladoc Health (Livongo), Omada Health, and Lark, distinguishing itself through a consolidated multi-condition ecosystem that mitigates "point solution fatigue" for its 125+ enterprise clients, including national health plans and large employers. The company is led by Co-founder and CEO Erez Raphael, who has overseen Dario’s pivot from a hardware-centric startup to a software-led enterprise since 2013. The leadership team was bolstered in mid-2025 by the appointment of Steven M. Nelson as President—bringing extensive scale experience from his roles as CEO of Contigo Health and COO of Anthem’s Diversified Business Group—alongside CFO Chen Franco-Yehuda. Other key executives include COO Lara Dodo and Chief Medical Officer Dr. Omar Manejwala. DarioHealth is supported by a board chaired by Yoav Shaked and features notable institutional backing from Perceptive Advisors and Sanofi. This executive pedigree, combined with strategic partnerships with payers like Aetna and Sentara Health, underscores the company's shift toward high-value, evidence-based enterprise contracts.